Other clinical trials are still ongoing for employing a PD-L1 blockade in combination with stereotactic radiation therapy (SRT) in stage I–IIIA NSCLC patients who are planned to undergo surgical resection of lung cancer (ClinicalTrials.gov Identifier: NCT03217071) or in combination with standard chemotherapy or EGFR-targeted therapies. Here, EGFR is linked to lung cancer.